SLC5A2 and diabetes mellitus: Of note, the SGLT2-I AMI PROTECT trial reported normal baseline HbA1c levels in the SGLT2-I and non SGLT2-I group suggesting that SGLT2-I treatment lowers diabetes-induced inflammation [39] independent of glucose lowering effect.